11/7
11:14 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $84.00 price target on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $84.00 price target on the stock.
11/7
08:36 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
11/6
04:13 pm
kros
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results [Yahoo! Finance]
11/6
04:01 pm
kros
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Low
Report
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
11/6
08:00 am
kros
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
Low
Report
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
11/6
06:33 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) was upgraded by analysts at Wedbush to a "strong-buy" rating.
Medium
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) was upgraded by analysts at Wedbush to a "strong-buy" rating.
11/5
02:01 pm
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
11/5
09:00 am
kros
Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition
Medium
Report
Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition
10/24
07:16 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
10/16
08:44 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
10/16
08:00 am
kros
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer
Low
Report
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer
9/23
07:59 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Guggenheim. They set a "buy" rating and a $96.00 price target on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Guggenheim. They set a "buy" rating and a $96.00 price target on the stock.
9/12
02:15 pm
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) had its price target lowered by analysts at Bank of America Co. from $81.00 to $76.00. They now have a "buy" rating on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) had its price target lowered by analysts at Bank of America Co. from $81.00 to $76.00. They now have a "buy" rating on the stock.
9/12
08:00 am
kros
Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference
Medium
Report
Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference
9/3
08:00 am
kros
Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial
Medium
Report
Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial
8/28
08:00 am
kros
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Low
Report
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences